BioCentury
ARTICLE | Company News

Alize Pharma, Jazz Pharmaceuticals deal

May 23, 2016 7:00 AM UTC

Jazz acquired Alize’s Alize Pharma II S.A.S. company for EUR8 million ($9.1 million) in cash up front, plus up to EUR10 million ($11.3 million) in cash in potential regulatory milestones. Alize Pharma II’s lead product, Asparec pegcrisantaspase, is a pegylated recombinant L-asparaginase from Erwinia chrysanthemi and is in Phase II/III testing to treat acute lymphoblastic leukemia (ALL). ...